Antitumor effect of combination of murine recombinant interferon β, murine recombinant interferon γ and human recombinant interleukin-2 in MethA-bearing mice
| Autor: | Naoko Sugimoto, Tsushima K, Yutaka Yoshida, Soh Saitoh, Yoshihiro Tamura, Hidekazu Suzuki, Hiromitsu Takemori, Yuh Sakata, Tohru Itoh, Ogasawara H |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
Interleukin 2 Cancer Research Cell Survival Fibrosarcoma medicine.medical_treatment Immunology Drug Administration Schedule law.invention Interferon-gamma Mice chemistry.chemical_compound law Interferon Antineoplastic Combined Chemotherapy Protocols Tumor Cells Cultured medicine Animals Humans Immunology and Allergy Interferon gamma Killer Cells Lymphokine-Activated Mice Inbred BALB C business.industry Macrophages Neoplasms Experimental Immunotherapy medicine.disease Virology Molecular biology Recombinant Proteins Killer Cells Natural Cytokine Oncology chemistry Interferon Type I Recombinant DNA Interleukin-2 Growth inhibition business Cell Division Neoplasm Transplantation medicine.drug |
| Zdroj: | Cancer Immunology Immunotherapy. 32:88-94 |
| ISSN: | 1432-0851 0340-7004 |
| DOI: | 10.1007/bf01754204 |
| Popis: | We have previously reported that the combination of murine recombinant interferon beta (Mu-rIFN beta) with murine recombinant interferon gamma (Mu-rIFN gamma) provided greater inhibition of tumor growth than did each one alone in MethA-bearing mice. In the present study the effect of addition of human recombinant interleukin-2 (Hu-rIL-2) to the combination of Mu-rIFN beta with Mu-rIFN gamma on tumor growth in BALB/c mice bearing syngeneic MethA fibrosarcoma was examined. Low doses of Hu-rIL-2 (5 x 10(3) U or 5 x 10(4) U at 3-day intervals) showed no antitumor activity, while a high dose of Hu-rIL-2 (5 x 10(5) U) showed profound growth inhibition. The administration of IL-2 (ranging between 5 x 10(3) U and 5 x 10(5) U) in addition to the combination of IFN beta and IFN gamma showed more augmented antitumor effects in a dose-dependent manner. Furthermore, the simultaneous administration of IL-2, IFN beta and IFN gamma had more effective therapeutic activity, compared with the sequential administration of interferons and IL-2. These findings indicated that IL-2 in combination with IFN beta and gamma was effective for cancer treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink